Research, Consulting and Supply Agreements (Details Narrative) - USD ($) |
1 Months Ended | 3 Months Ended | 6 Months Ended | 12 Months Ended | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
Aug. 15, 2026 |
Sep. 30, 2023 |
Sep. 30, 2022 |
Apr. 30, 2022 |
Jun. 30, 2026 |
Jun. 30, 2025 |
Jun. 30, 2026 |
Jun. 30, 2025 |
Dec. 31, 2023 |
Aug. 31, 2024 |
Oct. 31, 2023 |
|
| Research and development expense | $ 589,000 | $ 1,174,000 | $ 1,071,000 | $ 2,254,000 | |||||||
| Manufacturing estimated costs | $ 5,000 | $ 10,000 | 9,000 | 20,000 | |||||||
| Subsequent Event [Member] | Sterling Proposal Agreement [Member] | |||||||||||
| Manufacturing estimated costs | $ 1,500,000 | ||||||||||
| Amarex Clinical Research LLC [Member] | |||||||||||
| Research and development expense | $ 118,000 | $ 200,000 | |||||||||
| Research and development expense excluding acquired in process cost | $ 6,400,000 | $ 8,400,000 | |||||||||
| Development cost | 125,000 | $ 1,000,000 | $ 6,600,000 | ||||||||
| Invigilators cost | $ 4,400,000 | ||||||||||
| Azenova Sales International [Member] | |||||||||||
| Retainer amount | $ 10,000 | $ 30,000 | |||||||||
| Stock options, vested | 3,600 | ||||||||||
| Alcami [Member] | |||||||||||
| Research and development expense | $ 30,000 | ||||||||||